Literature DB >> 2031794

Effects of contrast media on the RR and QT interval during coronary arteriography.

M Mitsumori1, K Hayakawa, T Soga, M Maeda, T Torizuka, Y Okuno, T Misaki, S Dokoh.   

Abstract

During coronary arteriography, transient prolongation of the RR and QT intervals can be observed to occur. Animal experiments have suggested that low-osmolality contrast media have less effect, but there have been few clinical studies of this phenomenon. We analyzed 95 electrocardiographic records from patients who had undergone coronary arteriography and assessed the maximal prolongation of the RR and QT intervals. The contrast media used for arteriography included meglumine sodium diatrizoate, iopamidol, iohexol, and meglumine sodium ioxaglate. Diatrizoate caused the greatest electrocardiographic changes. Among the low osmolality contrast media, ioxaglate caused the smallest bradycardial effect and iohexol the smallest prolongation of the QT interval. It appears necessary to consider some additional factors for osmolality or ionicity, such as the chemotoxicity of the chemical structure of the iodinated contrast medium moiety, when assessing their potential adverse effect on the cardiac conduction system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2031794

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  2 in total

1.  Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.

Authors:  Christian Funck-Brentano; Mathieu Felices; Nathalie Le Fur; Corinne Dubourdieu; Pierre Desché; Frédéric Vanhoutte; Pascal Voiriot
Journal:  Br J Clin Pharmacol       Date:  2020-04-27       Impact factor: 4.335

2.  Iohexol contrast medium induces QT prolongation in amiodarone patients.

Authors:  Matthias Goernig; Thomas Kirmeier; Andreas Krack; Christiane S Hartog; Hans R Figulla; Uwe Leder
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.